A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-Cell Lymphoma, Stage II-IV.

Trial Profile

A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-Cell Lymphoma, Stage II-IV.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Acronyms HITT
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Apr 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 25 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top